Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

1. Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) - HIV

Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) - HIV Published 8 March 2021 1 Product update SMC2333 doravirine/lamivudine/tenofovir disoproxil fumarate 100mg/300mg/245mg film-coated tablets (Delstrigo®) Merck Sharp & Dohme (UK) Limited 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is accepted for use within NHSScotland. Indication under review: for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir. Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) offers an additional treatment choice

2021 Scottish Medicines Consortium

2. Doravirine (Pifeltro) - HIV

Doravirine (Pifeltro) - HIV Published 8 March 2021 1 Product update SMC2332 doravirine 100mg film-coated tablets (Pifeltro®) Merck Sharp & Dohme (UK) Limited 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission doravirine (...) (Pifeltro®) is accepted for use within NHSScotland. Indication under review: in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Doravirine offers an additional treatment choice in the therapeutic class of NNRTIs for this indication. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS

2021 Scottish Medicines Consortium

3. Best practices of using online and geosocial network applications to provide HIV and sexual health information to young newcomer men who have sex with men

Control and Prevention, Chinese Center for Disease Control and Prevention. Description of AIDS health education database. 2015. Available from: Accessed January 8, 2021. Smith MK, Cao B, Fu R, Zhao Y, Liu C, Lazard AJ, et al. Leveraging crowdsourcing for human immunodeficiency virus testing posters: A visual content analysis and cognitive responses among Chinese men who have sex with men. Sexually Transmitted Diseases. 2020;47(9):580–6. Tang W, Han L, Best J, Zhang Y, Mollan K, Kim J, et al (...) on Reddit (34). There are other gay apps operating in China, but they are much smaller in terms of user numbers (34). Blued has incorporated community-driven HIV prevention messaging into the application and includes basic facts about the virus, as well as information on prevention, testing and treatment options, and how and where to contact related services (35). Interactive quizzes test users’ knowledge about HIV (35). A 2019 study examined the results of a voting feature on the Blued application

2021 Ontario HIV Treatment Network

4. Laboratory (non-rapid) HIV testing in the emergency department: Methods, outcomes, and effectiveness

searched. The searches yielded 365 references from which 63 were included. Reference list Torian LV, Felsen UR, Xia Q, Laraque F, Rude EJ, Rose H, et al. Undiagnosed HIV and HCV infection in a New York City emergency department, 2015. American Journal of Public Health. 2018;108(5):652–8. Furukawa NW, Blau EF, Reau Z, Carlson D, Raney ZD, Johnson TK, et al. Missed opportunities for human immunodeficiency virus (HIV) testing during injection drug use-related healthcare encounters among a cohort (...) for HIV, hepatitis B and hepatitis C: Observational study of screening acceptance, yield and treatment outcomes. Emergency Medicine Journal. 2020;37(2):102–5. Rucker MG, Eavou R, Allgood KL, Sinclair D, Lawal R, Tobin A, et al. Implementing routine HIV screening in three Chicago hospitals: Lessons learned. Public Health Reports. 2016;131 Suppl 1:121–9. Sha BE, Kniuksta R, Exner K, Kishen E, Shankaran S, Williams B, et al. Evolution of an electronic health record based-human immunodeficiency virus (HIV

2021 Ontario HIV Treatment Network

5. Cabotegravir and rilpivirine (Cabenuva) - To treat HIV

Cabotegravir and rilpivirine (Cabenuva) - To treat HIV Drug Approval Package: VOCABRIA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: VOCABRIA Company: ViiV Healthcare Company Application Number: 212887Orig1s000,212888Orig1s000 Approval Date: 1/21/2021 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF

2021 FDA - Drug Approval Package

6. HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring

HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring HIV Pre-Exposure Prophylaxis (...) in the EU/EEA and the UK: implementation, standards and monitoring Technical guidance 5 Mar 2021 Cite: European Centre for Disease Prevention and Control. HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring. Operational guidance. Stockholm: ECDC; 2021. This operational guidance document provides practical recommendations and key considerations to inform the development and implementation of PrEP programmes at national and sub-national levels throughout the EU

2021 European Centre for Disease Prevention and Control - Technical Guidance

7. Management of tuberculosis in adults living with HIV (2021 interim update)

in adults living with HIV 7 1 Scope and purpose The overall purpose of these guidelines is to help physicians manage adults with tuberculosis (TB)/human immunodeficiency virus (HIV) co-infection. Recommendations for the treatment of TB in HIV-positive adults are similar to those in HIV-negative adults. Of note, the term ‘HIV’ refers to HIV-1 throughout these guidelines. 1.1 Guideline development process The British HIV Association (BHIVA) fully revised and updated the Association’s guideline development (...) inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157: 313–324. 11. Török ME, Yen NT, Chau TT et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374–1383. 12. Boulle A, Van Cutsem G, Cohen K et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based

2021 British HIV Association

8. Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial Full Text available with Trip Pro

, Mchugh G, Metcalfe J, et al. . Chronic lung disease in HIV-infected children established on antiretroviral therapy. AIDS. 2016;30(18):2795-2803. doi:10.1097/QAD.0000000000001249 - - - Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr Pulmonol. 2008;43(1):1-10. doi:10.1002/ppul.20676 - - Gona P, Van Dyke RB, Williams PL, et al. . Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296(3):292-300. doi:10.1001 (...) Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19

2021 EvidenceUpdates

9. What is the evidence for cost-effectiveness of testing for HIV, Hepatitis B and Hepatitis C in primary care and other settings in the UK?

, Hepatitis B and Hepatitis C in primary care and other settings in the UK? KLS Evidence Briefing 22nd January 2021 Background This briefing summarises literature on the cost-effectiveness of testing in UK primary care settings for HIV, Hepatitis B virus (HBV) and Hepatitis C virus (HCV). Testing for these viruses in other settings, including secondary care was of secondary interest, and literature on this topic is also included in the briefing. It has been estimated that over 100,000 people in the UK (...) ((hepatitis c or hepatitis b) adj1 (test* or screen*)).ab. /freq=2 10 ((hepatitis c or hepatitis b) adj1 (test* or screen*)).ti. 11 (blood borne virus* adj1 (test* or screen*)).tw. 12 ((HBV or HCV) adj1 (test* or screen*)).tw. 13 or/7-12 14 (mass adj1 (test* or screen*)).tw. 15 (opt-out adj1 (test* or screen*)).tw. 16 (opportunistic* adj1 (test* or screen*)).tw. 17 (routine adj1 (test* or screen*)).tw. 18 (point of care adj3 (test* or screen*)).tw. 19 case finding.tw. 20 or/14-19 21 (HIV or hepatitis C

2021 Public Health England - Evidence Briefings

10. Fostemsavir (Rukobia) - human immunodeficiency virus type 1 (HIV-1)

Fostemsavir (Rukobia) - human immunodeficiency virus type 1 (HIV-1) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/707937/2020 EMEA/H/C/005011 Rukobia (fostemsavir (...) ) An overview of Rukobia and why it is authorised in the EU What is Rukobia and what is it used for? Rukobia is a medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Rukobia is given with other HIV medicines when none of the standard combinations work well enough to control the infection because the virus is resistant to them (multi-drug resistant HIV-1). How is Rukobia used? Rukobia can only be obtained

2021 European Medicines Agency - EPARs

11. Rilpivirine (Rekambys) - human immunodeficiency virus type 1 (HIV-1)

Rilpivirine (Rekambys) - human immunodeficiency virus type 1 (HIV-1) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/565630/2020 EMEA/H/C/005060 Rekambys (rilpivirine (...) ) An overview of Rekambys and why it is authorised in the EU What is Rekambys and what is it used for? Rekambys is used together with another medicine called cabotegravir to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is used in adults whose infection is under control with other HIV medicines. Rekambys contains the active substance rilpivirine. How is Rekambys used? Rekambys is available as a prolonged-release

2021 European Medicines Agency - EPARs

12. Cabotegravir (Vocabria) - human immunodeficiency virus type 1 (HIV-1)

Cabotegravir (Vocabria) - human immunodeficiency virus type 1 (HIV-1) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/565621/2020 EMEA/H/C/004976 Vocabria (cabotegravir (...) ) An overview of Vocabria and why it is authorised in the EU What is Vocabria and what is it used for? Vocabria is used together with another medicine called rilpivirine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is used in adults whose infection is under control with antiretroviral medicines (medicines for HIV). Vocabria contains the active substance cabotegravir. How is Vocabria used? Vocabria is available

2021 European Medicines Agency - EPARs

13. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial Full Text available with Trip Pro

: 24852077 Review. References DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington (DC): Department of Health and Human Services; 2020. [cited 2020 Oct 16]. . European AIDS Clinical Society. EACS guidelines 2020. Version 10.1. Brussels: European AIDS Clinical Society; 2020. [cited 2020 Oct 20]. . Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, et al. Dual therapy treatment strategies (...) Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2021 EvidenceUpdates

14. Darunavir / cobicistat (Rezolsta) - treatment of human immunodeficiency virus 1 (HIV 1)

Darunavir / cobicistat (Rezolsta) - treatment of human immunodeficiency virus 1 (HIV 1) Final Appraisal Recommendation Advice No: 1220 – November 2020 Darunavir/cobicistat (Rezolsta ® ) 800mg/150mg film-coated tablets Limited submission by Janssen-Cilag Ltd Additional note(s): ? This advice incorporates and replaces the existing AWMSG recommendation for darunavir/cobicistat (Rezolsta ® ) as an option for use within NHS Wales in combination with other antiretroviral medicinal products (...) for the treatment of human immunodeficiency virus-1 (HIV 1) infection in adults aged 18 years or older (Advice number 2115, originally published September 2015). In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3779), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available

2020 All Wales Medicines Strategy Group

15. Impact of providing free HIV self-testing kits on frequency of testing among men who have sex with men and their sexual partners in China: A randomized controlled trial Full Text available with Trip Pro

Impact of providing free HIV self-testing kits on frequency of testing among men who have sex with men and their sexual partners in China: A randomized controlled trial Impact of providing free HIV self-testing kits on frequency of testing among men who have sex with men and their sexual partners in China: A randomized controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) navigation PLoS Med Actions . 2020 Oct 9;17(10):e1003365. doi: 10.1371/journal.pmed.1003365. eCollection 2020 Oct. Impact of providing free HIV self-testing kits on frequency of testing among men who have sex with men and their sexual partners in China: A randomized controlled trial , , , , , , Affiliations Expand Affiliations 1 Xiangya School of Nursing, Central South University, Changsha, Hunan Province, China. 2 School of Nursing, University of California at Los Angeles, Los Angeles, California

2020 EvidenceUpdates

16. The impact of continuous quality improvement on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-randomised controlled implementation trial Full Text available with Trip Pro

Research Support, N.I.H., Extramural Actions Research Support, Non-U.S. Gov't Actions MeSH terms Adult Actions Anti-HIV Agents / therapeutic use Actions Female Actions HIV Infections / blood Actions HIV Infections / diagnosis Actions HIV Infections / drug therapy Actions HIV Infections / prevention & control* Actions HIV Seropositivity / diagnosis Actions Humans Actions Implementation Science Actions Infectious Disease Transmission, Vertical / prevention & control* Actions Practice Patterns, Nurses (...) The impact of continuous quality improvement on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-randomised controlled implementation trial The impact of continuous quality improvement on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-randomised controlled implementation trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features

2020 EvidenceUpdates

17. Case management and patient navigation models for people living with or at risk of HIV

Health Department. Their recommended qualifications for a non-medical case manager included: 1) possess at least an associate’s degree in health, human, or education services, and 2) have one or more years of case management experience with people living with HIV, and/or persons with a history of mental illness, homelessness, or chemical dependence (21). Patient navigation services were initially created as a way to increase timely access to cancer care among marginalized populations, and its (...) J. The Open Arms Healthcare Center’s integrated HIV care services model. Preventing Chronic Disease. 2019;16:E135. Broaddus MR, Owczarzak J, Schumann C, Koester KA. Fostering a “feeling of worth” among vulnerable HIV populations: The role of linkage to care specialists. AIDS Patient Care & STDs. 2017;31(10):438–46. Yanes-Lane M, Dussault C, Linthwaite B, Cox J, Klein MB, Sebastiani G, et al. Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage

2020 Ontario HIV Treatment Network

18. Effect of 2 Integrated Interventions on Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous Alcohol Use and HIV: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of 2 Integrated Interventions on Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous Alcohol Use and HIV: A Randomized Clinical Trial Effect of 2 Integrated Interventions on Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous Alcohol Use and HIV: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) Netw Open Actions . 2020 Sep 1;3(9):e2017115. doi: 10.1001/jamanetworkopen.2020.17115. Effect of 2 Integrated Interventions on Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous Alcohol Use and HIV: A Randomized Clinical Trial , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. 2 Department of Psychiatry and Behavioral Sciences, School

2020 EvidenceUpdates

19. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America Full Text available with Trip Pro

Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America | Clinical Infectious Diseases | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies (...) . You can change your cookie settings at any time. Advertisement Navbar Search Filter Mobile Microsite Search Term search filter search input Article Navigation Close mobile search navigation Article Navigation Article Contents Article Navigation Corrected proof Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America , Melanie A Thompson AIDS Research Consortium of Atlanta , Atlanta, Georgia, USA

2020 Infectious Diseases Society of America

20. Testing interventions for HIV and sexually transmitted infections (STIs) among young men who have sex with men

behaviors among sexually-active young gay, bisexual, and other men who have sex with men and transgender women. AIDS & Behavior. 2018;22(2):522–30. Pharr JR, Lough NL, Ezeanolue EE. Barriers to HIV testing among among young men who have sex with men (MSM): Experiences from Clark County, Nevada. Global Journal of Health Science. 2015;8(7):9–17. Phillips G, 2nd, Ybarra ML, Prescott TL, Parsons JT, Mustanski B. Low rates of human immunodeficiency virus testing among adolescent gay, bisexual, and queer men (...) with undiagnosed HIV are among youth aged 13–24 (19). HIV testing is important, as identifying the virus encourages linkage to care for antiretroviral therapy, in addition to preventing secondary transmission (4, 20). Trends in the uptake of HIV and STI testing among young men who have sex with men is well-established in the literature: A systematic review among studies (n=32; 2005–2014) reporting HIV testing behaviours among Internet-using men who have sex with men in the U.S. (n=83,186) found that younger

2020 Ontario HIV Treatment Network